Clinical experiment designed to assess clinical efficacy targeting DLB in human. Primary outcome: Validate Tau Co-Pathology in DLB Clinical Heterogeneity
Description
Tau Co-Pathology in DLB Clinical Heterogeneity
Background and Rationale
Dementia with Lewy bodies (DLB) represents the second most common neurodegenerative dementia, characterized by alpha-synuclein pathology. However, 30-50% of DLB cases exhibit concomitant tau pathology, creating significant clinical heterogeneity that complicates diagnosis, prognosis, and treatment selection. This tau co-pathology may explain the variable presentation of core DLB features including cognitive fluctuations, visual hallucinations, REM sleep behavior disorder, and parkinsonism. Current diagnostic approaches fail to stratify patients based on underlying pathological burden, leading to suboptimal therapeutic outcomes. This prospective longitudinal cohort study will recruit 200 clinically diagnosed DLB patients and 50 age-matched controls to investigate how tau co-pathology influences disease phenotype and progression. Participants will undergo comprehensive clinical assessment, neuropsychological testing, and advanced neuroimaging including tau PET ([18F]MK-6240), amyloid PET, and multimodal MRI....
Tau Co-Pathology in DLB Clinical Heterogeneity
Background and Rationale
Dementia with Lewy bodies (DLB) represents the second most common neurodegenerative dementia, characterized by alpha-synuclein pathology. However, 30-50% of DLB cases exhibit concomitant tau pathology, creating significant clinical heterogeneity that complicates diagnosis, prognosis, and treatment selection. This tau co-pathology may explain the variable presentation of core DLB features including cognitive fluctuations, visual hallucinations, REM sleep behavior disorder, and parkinsonism. Current diagnostic approaches fail to stratify patients based on underlying pathological burden, leading to suboptimal therapeutic outcomes. This prospective longitudinal cohort study will recruit 200 clinically diagnosed DLB patients and 50 age-matched controls to investigate how tau co-pathology influences disease phenotype and progression. Participants will undergo comprehensive clinical assessment, neuropsychological testing, and advanced neuroimaging including tau PET ([18F]MK-6240), amyloid PET, and multimodal MRI. The study will employ a 24-month follow-up design with assessments every 6 months to capture disease progression patterns. Primary objectives include determining whether tau-positive DLB patients exhibit distinct clinical phenotypes, faster cognitive decline, different treatment responses to cholinesterase inhibitors and levodopa, and altered survival outcomes. Secondary aims focus on validating tau PET imaging as a biomarker for patient stratification and treatment selection. This research addresses a critical knowledge gap in DLB pathophysiology and has immediate translational potential for precision medicine approaches. The innovation lies in combining advanced molecular imaging with detailed phenotyping to create pathology-based patient subtypes. Results will inform clinical trial design, enable personalized treatment strategies, and potentially identify novel therapeutic targets for tau-positive DLB variants.
This experiment directly tests predictions arising from the following hypotheses:
Enteric Nervous System Prion-Like Propagation Blockade
Gut Barrier Permeability-α-Synuclein Axis Modulation
Noradrenergic-Tau Propagation Blockade
Tau-Independent Microtubule Stabilization via MAP6 Enhancement
Experimental Protocol
Phase 1 (Months 1-6): Recruit 200 DLB patients meeting consensus criteria and 50 cognitively normal controls. Obtain informed consent, medical history, and baseline demographics. Phase 2 (Months 4-12): Conduct comprehensive baseline assessments including Unified Parkinson's Disease Rating Scale (UPDRS), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), and Montreal Cognitive Assessment (MoCA). Perform tau PET imaging using [18F]MK-6240 tracer (370 MBq injection, 90-110 minute post-injection scanning), amyloid PET with [18F]florbetapir, and 3T MRI with structural, diffusion tensor, and resting-state sequences. Phase 3 (Months 6-24): Implement 6-month follow-up visits with repeated clinical assessments, medication tracking, and adverse event monitoring. Perform annual repeat tau PET imaging in subset of 100 patients. Collect cerebrospinal fluid at baseline and 12 months for tau, phospho-tau, and alpha-synuclein quantification using ELISA and Simoa platforms. Phase 4 (Months 18-30): Analyze tau PET standardized uptake value ratios (SUVRs) using cerebellar reference region. Define tau-positivity threshold using Gaussian mixture modeling. Correlate regional tau burden with clinical phenotypes using multivariate regression analyses. Assess treatment response differences between tau-positive and tau-negative groups using mixed-effects models controlling for age, sex, disease duration, and baseline severity.
Expected Outcomes
Tau-positive DLB patients (35-45% of cohort) will demonstrate 40-60% greater annual cognitive decline rates compared to tau-negative cases (p<0.001, effect size d=0.8)
Distinct clinical phenotype in tau-positive group featuring earlier onset dementia, reduced visual hallucinations (OR=0.3, 95% CI 0.15-0.6), and greater executive dysfunction
Tau PET SUVRs in temporal and parietal regions will correlate with cognitive severity (r=0.6-0.8, p<0.001) and predict progression rates with 85% accuracy
Reduced cholinesterase inhibitor efficacy in tau-positive patients with 50% smaller improvement in cognitive scores compared to tau-negative group (p<0.01)
Increased mortality risk in tau-positive DLB with hazard ratio of 2.1 (95% CI 1.3-3.4, p<0.005) over 24-month follow-up
Regional tau distribution patterns will identify 3-4 distinct DLB subtypes with different progression trajectories and treatment responses
Success Criteria
• Achieve statistical significance (p<0.05) for primary endpoint comparing cognitive decline rates between tau-positive and tau-negative DLB groups
• Demonstrate tau PET diagnostic accuracy >80% for distinguishing DLB phenotypes with area under ROC curve >0.85
• Complete longitudinal follow-up in >85% of enrolled participants with <15% dropout rate over 24 months
• Establish tau-positivity threshold with >90% inter-rater reliability and validation in independent cohort of 50 patients
• Identify significant treatment response differences between groups with effect size >0.5 for at least two therapeutic interventions
• Develop and validate prognostic model incorporating tau burden that improves survival prediction accuracy by >20% compared to clinical variables alone
TARGET GENE
DLB
MODEL SYSTEM
human
ESTIMATED COST
$5,460,000
TIMELINE
45 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Validate Tau Co-Pathology in DLB Clinical Heterogeneity
Phase 1 (Months 1-6): Recruit 200 DLB patients meeting consensus criteria and 50 cognitively normal controls. Obtain informed consent, medical history, and baseline demographics. Phase 2 (Months 4-12): Conduct comprehensive baseline assessments including Unified Parkinson's Disease Rating Scale (UPDRS), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), and Montreal Cognitive Assessment (MoCA). Perform tau PET imaging using [18F]MK-6240 tracer (370 MBq injection, 90-110 minute post-injection scanning), amyloid PET with [18F]florbetapir, and 3T MRI with structural, diffusion tensor, and resting-state sequences. Phase 3 (Months 6-24): Implement 6-month follow-up visits with repeated clinical assessments, medication tracking, and adverse event monitoring.
...
Phase 1 (Months 1-6): Recruit 200 DLB patients meeting consensus criteria and 50 cognitively normal controls. Obtain informed consent, medical history, and baseline demographics. Phase 2 (Months 4-12): Conduct comprehensive baseline assessments including Unified Parkinson's Disease Rating Scale (UPDRS), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), and Montreal Cognitive Assessment (MoCA). Perform tau PET imaging using [18F]MK-6240 tracer (370 MBq injection, 90-110 minute post-injection scanning), amyloid PET with [18F]florbetapir, and 3T MRI with structural, diffusion tensor, and resting-state sequences. Phase 3 (Months 6-24): Implement 6-month follow-up visits with repeated clinical assessments, medication tracking, and adverse event monitoring. Perform annual repeat tau PET imaging in subset of 100 patients. Collect cerebrospinal fluid at baseline and 12 months for tau, phospho-tau, and alpha-synuclein quantification using ELISA and Simoa platforms. Phase 4 (Months 18-30): Analyze tau PET standardized uptake value ratios (SUVRs) using cerebellar reference region. Define tau-positivity threshold using Gaussian mixture modeling. Correlate regional tau burden with clinical phenotypes using multivariate regression analyses. Assess treatment response differences between tau-positive and tau-negative groups using mixed-effects models controlling for age, sex, disease duration, and baseline severity.
Expected Outcomes
Tau-positive DLB patients (35-45% of cohort) will demonstrate 40-60% greater annual cognitive decline rates compared to tau-negative cases (p<0.001, effect size d=0.8)
Distinct clinical phenotype in tau-positive group featuring earlier onset dementia, reduced visual hallucinations (OR=0.3, 95% CI 0.15-0.6), and greater executive dysfunction
Tau PET SUVRs in temporal and parietal regions will correlate with cognitive severity (r=0.6-0.8, p<0.001) and predict progression rates with 85% accuracy
Reduced cholinesterase inhibitor efficacy in tau-positive patients with 50% smaller improvement
...
Tau-positive DLB patients (35-45% of cohort) will demonstrate 40-60% greater annual cognitive decline rates compared to tau-negative cases (p<0.001, effect size d=0.8)
Distinct clinical phenotype in tau-positive group featuring earlier onset dementia, reduced visual hallucinations (OR=0.3, 95% CI 0.15-0.6), and greater executive dysfunction
Tau PET SUVRs in temporal and parietal regions will correlate with cognitive severity (r=0.6-0.8, p<0.001) and predict progression rates with 85% accuracy
Reduced cholinesterase inhibitor efficacy in tau-positive patients with 50% smaller improvement in cognitive scores compared to tau-negative group (p<0.01)
Increased mortality risk in tau-positive DLB with hazard ratio of 2.1 (95% CI 1.3-3.4, p<0.005) over 24-month follow-up
Regional tau distribution patterns will identify 3-4 distinct DLB subtypes with different progression trajectories and treatment responses
Success Criteria
• Achieve statistical significance (p<0.05) for primary endpoint comparing cognitive decline rates between tau-positive and tau-negative DLB groups
• Demonstrate tau PET diagnostic accuracy >80% for distinguishing DLB phenotypes with area under ROC curve >0.85
• Complete longitudinal follow-up in >85% of enrolled participants with <15% dropout rate over 24 months
• Establish tau-positivity threshold with >90% inter-rater reliability and validation in independent cohort of 50 patients
• Identify significant treatment response differences between groups with effect size >0.5 for at leas
...
• Achieve statistical significance (p<0.05) for primary endpoint comparing cognitive decline rates between tau-positive and tau-negative DLB groups
• Demonstrate tau PET diagnostic accuracy >80% for distinguishing DLB phenotypes with area under ROC curve >0.85
• Complete longitudinal follow-up in >85% of enrolled participants with <15% dropout rate over 24 months
• Establish tau-positivity threshold with >90% inter-rater reliability and validation in independent cohort of 50 patients
• Identify significant treatment response differences between groups with effect size >0.5 for at least two therapeutic interventions
• Develop and validate prognostic model incorporating tau burden that improves survival prediction accuracy by >20% compared to clinical variables alone